Skip to main content
. 2022 Jul 22;11(7):3693–3698. doi: 10.4103/jfmpc.jfmpc_2468_21

Table 6.

Adverse events among the moderately ill COVID-19 patients during remdesivir therapy percentage

Type of adverse event/Reaction Attributable to Percentage (n=32)
Elevated liver enzymes -ALT Remdesivir 17 (53.12%)
Elevated blood sugar levels Steroid (Dexamethasone) 18 (56.25%)
Increased oxygen requirement Disease process 4 (12.5%)
Hemoptysis 1 (3.1%)